Deficiency in the homologous recombination repair system represents up to 50% of ovarian, breast, prostate, and pancreatic cancers. While Poly ADP-ribose polymerase inhibitors (PARPi) treatment revolutionized the management of patients, inducing synthetic lethality in cells with homologous recombination deficiency (HRD), detection of HRD is challenging.
Indeed, homologous recombination repair (HRR) genetic testing does not suffice to determine with certainty HRD status, and researchers use the indirect genomic instability score to evaluate genomic scars or mutational signatures resulting from HRD.
Implementing methods able to detect HRD is crucial for identifying patients who could benefit from treatment with PARPi.
In this webinar, Prof. Alexandre Harlé will share his experience in HRD detection of ovarian cancers using SOPHiA GENETICS deep learning-based solution. Therefore, you will have the opportunity to discover:
- Current challenges for the implementation of HRD testing
- The analytical performance evaluation of the Genomic Integrity Index (GII) provided by the SOPHiA DDM™ HRD Solution
- The concordance of the HRD status obtained by GII with that obtained from the standard method
Disclaimer notice: The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are these of the speaker and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
When?
Friday, July 22, 2022 · 2:00 p.m.
Bern
Duration: 1 hour
Price
Free
Language
English
Who can attend
Everyone
Dial-in available? (listen only)
Not available.
Hosted By SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology company revolutionizing data-driven medicine and life sciences research. Their flagship product, the SOPHiA DDM™ Platform, empowers over 750 global institutions with cloud-based analytics and insights from diverse diagnostic datasets.
Biologist/Professor of theliquid biopsy and tumour heterogeneity group at Institut de Cancérologie de Lorraine-Alexis Vautrin, Nancy, France.
Pr. Harlé earned his doctoral degree in 2014 with a specialization in Oncology and biomarkers from the University of Lorraine, Nancy, France. He is now laboratory head of the liquid biopsy and tumour heterogeneity group and biologist at Institut...